EANO guideline on the diagnosis and management of meningiomas

R Goldbrunner, P Stavrinou, MD Jenkinson… - Neuro …, 2021 - academic.oup.com
Meningiomas are the most common intracranial tumors. Yet, only few controlled clinical trials
have been conducted to guide clinical decision making, resulting in variations of …

The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer

R Cunningham, CG Hansen - Clinical Science, 2022 - portlandpress.com
Tumorigenesis is a highly complex process, involving many interrelated and cross-acting
signalling pathways. One such pathway that has garnered much attention in the field of …

Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities

A Choudhury, ST Magill, CD Eaton, BC Prager… - Nature …, 2022 - nature.com
Meningiomas are the most common primary intracranial tumors. There are no effective
medical therapies for meningioma patients, and new treatments have been encumbered by …

[HTML][HTML] YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance

F Szulzewsky, EC Holland, V Vasioukhin - Developmental biology, 2021 - Elsevier
YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling
pathway. In addition to important functions in normal tissue homeostasis and regeneration …

Molecular alterations in meningioma: prognostic and therapeutic perspectives

C Birzu, M Peyre, F Sahm - Current opinion in oncology, 2020 - journals.lww.com
The mutational landscape of meningioma has expanded following the use of the new
genetic sequencing approaches. Novel mutations have been characterized and reveal their …

Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients

JZ Wang, AP Landry, DR Raleigh, F Sahm… - Neuro …, 2024 - academic.oup.com
Meningiomas are the most common primary intracranial tumors in adults and are increasing
in incidence due to the aging population and increased access to neuroimaging. While most …

Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis

F Szulzewsky, S Arora, P Hoellerbauer… - Genes & …, 2020 - genesdev.cshlp.org
YAP1 is a transcriptional coactivator and the principal effector of the Hippo signaling
pathway, which is causally implicated in human cancer. Several YAP1 gene fusions have …

Intracranial mesenchymal tumor with FET‐CREB fusion—a unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous …

EA Sloan, J Chiang, JE Villanueva‐Meyer… - Brain …, 2021 - Wiley Online Library
Intracranial mesenchymal tumors with FET‐CREB fusions are a recently described group of
neoplasms in children and young adults characterized by fusion of a FET family gene …

The oncogenic fusion landscape in pediatric CNS neoplasms

M Roosen, Z Odé, J Bunt, M Kool - Acta Neuropathologica, 2022 - Springer
Pediatric neoplasms in the central nervous system (CNS) are the leading cause of cancer-
related deaths in children. Recent developments in molecular analyses have greatly …

Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2 mutant meningiomas in mice

F Szulzewsky, S Arora, AKS Arakaki… - Genes & …, 2022 - genesdev.cshlp.org
YAP1 is a transcriptional coactivator regulated by the Hippo signaling pathway, including
NF2. Meningiomas are the most common primary brain tumors; a large percentage exhibit …